Cytokinetics stock touches 52-week low at $41.69 amid market challenges
In a turbulent market environment, Cytokinetics , Incorporated (NASDAQ:CYTK) stock has reached its 52-week low, trading at $41.69, with a sharp 14% decline just last week. According to InvestingPro ...
Cytokinetics appoints Robert Landry to board of directors
Cytokinetics (CYTK) announced the appointment of Robert Landry to its Board of Directors. Mr. Landry brings over three decades of financial and ...
Cytokinetics Names Robert E. Landry to Board of Directors
Appointment Deepens Financial and Operational Expertise of Boardas Company Approaches Potential Commercialization SOUTH SAN ...
Why Cytokinetics, Incorporated (CYTK) Is Among the Best Healthcare Stocks To Buy According to Analysts
We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to ...
Fintel on MSN4d
Citigroup Initiates Coverage of Cytokinetics (CYTK) with Buy Recommendation
Fintel reports that on February 7, 2025, Citigroup initiated coverage of Cytokinetics (NasdaqGS:CYTK) with a Buy ...
Cytokinetics draws new Buy from Citi on aficamten potential
Cytokinetics (CYTK) was initiated by Citi analysts with a Buy rating, citing potential FDA approval for its lead asset ...
Camzyos news has negative readthroughs for Cytokinetics, says BofA
BofA notes that Cytokinetics (CYTK) shares are under pressure this morning after rival Bristol Myers (BMY) confirmed European regulators had ...